BERGISCH GLADBACH, Germany--27 Jun--PRNewswire/ InfoQuest
Miltenyi Biotec, the world's leading cell innovation company, announced today that it opened a new office in Seoul, Korea, enlarging the company's Asia-Pacific presence to six locations in five countries.
"Miltenyi Biotec recognizes the potential of a Korean presence in achieving strong, steady growth and expanding our global reach with a team of talented people," said CEO Boris Stoffel. "Our new team has an exceptional ability to partner with scientists and clinicians to generate exciting opportunities."
Daesuk Oh has been appointed General Manager of the new office in the Gangnam district of Seoul. "Our location will be instrumental in developing deeper relationships with a host of stem cell, immunology, translational research, and clinical customers, as well as prospective research and clinical institutions throughout South Korea. We're excited for the opportunity to bring Miltenyi Biotec's solutions to scientists and clinicians who can truly benefit from the quality and reliability the portfolio is known for," said Oh.
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance biomedical research. From research tools to GMP reagents, Miltenyi is making the promise of cell therapy a reality. The company's integrated portfolio of tools supports the translation of basic research into practical applications for human health. Scientists and clinicians around the world use Miltenyi-enabling technologies for effective sample preparation, cell isolation, flow cytometry, cell culture, molecular analysis and preclinical imaging. The MACS(R) brand has set standards in the industry and is trusted across basic, translational, and clinical research settings. The company also offers comprehensive technical support and training through its MACS(R) Academy. Miltenyi Biotec has 1,400 employees in 22 countries.
Media Contact:
Prof. Dr. Uwe Heinlein
Phone: +49-2204-8306-6590
E-mail: [email protected]
http://www.miltenyibiotec.com
Source: Miltenyi Biotec GmbH
SYNNEX charts its future at "SYNNEX PARTNER CONNECT 2025", Embracing the AI Ecosystem with Global Partnerships to Drive a Sustainable Digital Era
WHAUP Signals Continued Growth in the Second Half, Driven by Rising Demand from Data Centers
SCGD Accelerates Toward Net Zero 2050, Advancing Clean Energy Investments and Cost Reduction Through Digital Technology and Automation to Enhance Competitive Edge Across ASEAN
Ornsirin Education Invests 1,000 Million Baht to Make History with the Launch of Mill Hill International School Thailand - The First Authentic British-Branded International School in Chiang Mai
MoneyThunder's Impact in Helping One-Third of Customers Escape Informal Debt Earns ABACUS digital the "ESG DNA" Certificate for Social Responsibility
WINMED จับมือพันธมิตร Miltenyi Biotec ประเทศเยอรมัน จัดเสวนาออนไลน์ หัวข้อ "Cancer Immunotherapy: The Past, The Present, and The Possibility"